|Videos|November 21, 2015

Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Episodes in this series

EP. 1 Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

EP. 1 Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.

EP. 2 Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)

EP. 3 Dr. Anees Chagpar Named 2021 ASCO Fellow

Lieping Chen, MD, PhD

EP. 4 Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences

Roy S. Herbst, MD, PhD

EP. 5 Yale Research to be Presented at 2021 ASCO Annual Meeting

Jan Philipp Bewersdorf, MD, of Yale University School of Medicine

EP. 6 Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis

Barbara Burtness, MD

EP. 7 Barbara Burtness Named Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center

Joseph W. Kim, MD, of Yale Cancer Center

EP. 8 Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award

Roy S. Herbst, MD, PhD

EP. 9 Yale Cancer Center Perspective Highlights New Advances for NSCLC

Nikhil Joshi, PhD

EP. 10 Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

Andrea L. Silber, MD, of Yale Cancer Center

EP. 11 Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

EP. 12 Dr. Lustberg Discusses Ongoing Research in Breast Cancer

EP. 12 Dr. Lustberg Discusses Ongoing Research in Breast Cancer

Margaret Gilshannon, MHA

EP. 13 Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center

EP. 14 Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

EP. 14 Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

Eric P. Winer, MD, of Yale Cancer Center

EP. 15 Eric P. Winer to lead Yale Cancer Center and Smilow Cancer Hospital

Terri Parker, MD

EP. 16 Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

Qin Yan, PhD, of Yale Cancer Center

EP. 17 Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight Melanoma

Aileen I. Fernandez, PhD

EP. 18 Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

Aileen I. Fernandez, PhD

EP. 19 Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Roy S. Herbst, MD, PhD, of Yale Cancer Center

EP. 20 Immunotherapy Advances Drive Progress in Lung Cancer Treatment

Ian E. Krop, MD, PhD, of Yale Cancer Center

EP. 21 Ian E. Krop, MD, PhD, Named Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research at Yale Cancer Center

Natalia Neparidze, MD, of Yale Cancer Center

EP. 22 Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers

Alessandro Santin, MD

EP. 23 Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

Daniel P. Petrylak, MD

EP. 24 Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

Melinda Irwin, PhD, MPH

EP. 25 Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer

Aarti Bhatia, MD, associate professor of medicine at Yale School of Medicine and medical oncologist at Smilow Cancer Hospital at Yale, New Haven, Connecticut.

EP. 26 Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC

Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Chief Translational Research Officer, Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

EP. 27 Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital

Experts on SCLC

EP. 28 Expert Insights on First-line Treatment Strategies in SCLC

Experts on SCLC

EP. 29 Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

Experts on SCLC

EP. 30 ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

Experts on SCLC

EP. 31 Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

Experts on SCLC

EP. 32 Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

Experts on SCLC

EP. 33 Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

Experts on SCLC

EP. 34 Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

Experts on SCLC

EP. 35 LAGOON and IMFORTE Trials: Data Updates and Expert Insights

Experts on SCLC

EP. 36 2L Dosing Considerations and Management Strategies for SCLC

Experts on SCLC

EP. 37 Novel Treatment Approaches for SCLC and Future Perspectives

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Cholangiocarcinoma | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

August 28th, 2026

China's NMPA Approves Fanregratinib for Pretreated FGFR2+ Intrahepatic Cholangiocarcinoma

The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.

UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.

August 22nd, 2026

The OncFive: Top Oncology Articles for the Week of 8/16

UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

The OncFive: Top Oncology Articles for the Week of 8/30